1.	Phase II Study of Vaccination with Synthetic Melanoma Peptide Administered with Sargramostin (GM-CSF) Plus Interleukin-2 in Patients with Advanced Melanoma (Summary Last Modified 04/2002) Phase: Phase II Type: Treatment Status: Closed Age: 18-79 Sponsor: NCI Protocol IDs: UVACC-HIC-7621, UVA-HIC-7621, NCI-G98-1389, NCT00003222
2.	Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000335055, U10CA021115, ECOG-E1602, E1602, NCT00071981
3.	Phase I Study of Peptide 946 Melanoma Vaccine (Peptide 946), Peptide 946 Combined with Tetanus Peptide Melanoma Vaccine, or Peptide 946-Tetanus Peptide Conjugate in Patients with High Risk Melanoma (Summary Last Modified 05/2000) Phase: Phase I Type: Treatment Status: Closed Age: 18 to 79 Sponsor: NCI Protocol IDs: UVACC-HIC-6346, UVA-HIC-6346, NCI-H98-0010, NCT00003224